BioSpace News Archive

Plasma exchange is a procedure that separates and removes plasma from the blood in order to eliminate a disease substance circulating in the plasma.

Access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie, Biogen Inc. and Pfizer.

Neurocrine Biosciences, Inc. announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at 12:00 p.m. Eastern Time on Thursday July 15, 2021.

Veracyte, Inc. announced that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29.

The rapid proliferation of emerging technologies like Artificial Intelligence and Machine Learning to achieve greater efficiency in healthcare services is expected to drive the market demand.

Palatin Technologies, Inc. announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021 and was adjourned to July 8, 2021, has been adjourned until August 6, 2021 at 9:00 a.m. Eastern Daylight Time to allow Palatin to solicit additional proxies for Proposal 3, approval of an amendment to our Certificate of Incorporation to effect an increase in authorized common stock from 300,000,000 shares to 400,000,000 shares.

Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021.

ScreenPro Security Inc. (CSE: SCRN) (“ScreenPro” or the “Company”) is pleased to provide an update on COVID-19 testing numbers for the month of June. The Company provided services to production companies in Toronto and Vancouver and completed approximately 18,500 tests in June.

RNA Disease Diagnostics, Inc., a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced the appointment of Richard G. Ganz to its Board of Directors.

Medolife Rx, Inc. (“Medolife”), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today new clinical observations made on its lead drug candidate Escozine®.